1cBio

Executive Summary

1cBio, Inc. is a private biopharmaceutical company founded in 2022 and headquartered in the San Francisco Bay Area. The company operates at the preclinical to Phase 1/2 stage, focusing on converting transformative scientific ideas into novel small-molecule therapies. While specific pipeline details are not publicly disclosed, 1cBio's positioning in the competitive Bay Area biotech ecosystem and its early-stage status suggest a high-risk, high-reward profile typical of emerging biotechs. The company lacks disclosed funding, valuation, or revenue data, indicating a very early corporate development phase. Without clear clinical assets or partnerships, 1cBio's value proposition remains unproven, though its commitment to innovative science may attract future investment or collaboration.

Upcoming Catalysts (preview)

• TBDInitiation of first-in-human Phase 1 trial20% success
• TBDPublication of preclinical proof-of-concept data40% success
• TBDSeries A financing or strategic partnership announcement30% success